Coxsackievirus B3 VLPs purified by ion exchange chromatography elicit strong immune responses in mice

Koho, Tiia; Koivunen, Minni R. L.; Oikarinen, Sami; Kummola, Laura; Mäkinen, Selina; Sioofy‐Khojine, Amir‐Babak; Marjomäki, Varpu; Kazmertsuk, Artur; Junttila, Ilkka; Kulomaa, Markku S.; Hyöty, Heikki; Hytönen, Vesa P.; Laitinen, Olli H.

doi:10.1016/j.antiviral.2014.01.013

Cited by 40 publications

(49 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Nevertheless, experimentally, various vaccination strategies, such as the use of CVB3 virus-like particles, attenuated viral strains, and priming and boosting with CVB3 DNA and recombinant viral protein, respectively, have been shown to effectively confer varying degrees of protection [133-136]. …”

Section: Therapeutic Implicationsmentioning

confidence: 99%

Intricacies of cardiac damage in coxsackievirus B3 infection: Implications for therapy

Massilamany

Gangaplara

Reddy

2014

International Journal of Cardiology

View full text Add to dashboard Cite

Heart disease is the leading cause of death in humans, and myocarditis is one predominant cause of heart failure in young adults. Patients affected with myocarditis can develop dilated cardiomyopathy (DCM), a common reason for heart transplantation, which to date is the only viable option for combatting DCM. Myocarditis/DCM patients show antibodies to coxsackievirus B (CVB)3 and cardiac antigens, suggesting a role for CVB-mediated autoimmunity in the disease pathogenesis; however, a direct causal link remains to be determined clinically. Experimentally, myocarditis can be induced in susceptible strains of mice using the human isolates of CVB3, and the disease pathogenesis of postinfectious myocarditis resembles that of human disease, making the observations made in animals relevant to humans. In this review, we discuss the complex nature of CVB3-induced myocarditis as it relates to the damage caused by both the virus and the host's response to infection. Based on recent data we obtained in the mouse model of CVB3 infection, we provide evidence to suggest that CVB3 infection accompanies the generation of cardiac myosin-specific CD4 T cells that can transfer the disease to naïve recipients. The therapeutic implications of these observations are also discussed.

show abstract

Section: Therapeutic Implicationsmentioning

confidence: 99%

Intricacies of cardiac damage in coxsackievirus B3 infection: Implications for therapy

Massilamany

Gangaplara

Reddy

2014

International Journal of Cardiology

View full text Add to dashboard Cite

show abstract

“…However, VLPs were less immunogenic than a formalin-inactivated CV-B3 vaccine used as positive control and challenge experiments were not performed. 182 The immunoprotective ability of a recombinant vesicular stomatitis virus (VSV) vector expressing CV-B3 VP1 was compared to that of a chitosan-pDNA-VP1 vaccine following intranasal administration. The VSV-VP1 vaccine induced significantly higher levels of antigen-specific, systemic and mucosal antibody responses than chitosan-pDNA-VP1 as well as strong polyfunctional T-cell responses and dendritic cell maturation, but was not fully protective against a 50% lethal dose of live CV-B3.…”

Section: Development Of a Bivalent Ev-a71/cv-a16 Vaccinementioning

confidence: 99%

Is a multivalent hand, foot, and mouth disease vaccine feasible?

Klein¹,

Chong

2015

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

Keywords: bivalent and multivalent vaccines, coxsackievirus A16, coxsackieviruses B3 and B5, echovirus 30, epidemiology, enterovirus A (EV-A), enterovirus A71, hand, foot and mouth diseases, inactivated whole virion vaccines, monovalent, EV-A71 vaccine Enterovirus A infections are the primary cause of hand, foot and mouth disease (HFMD) in infants and young children. Although enterovirus 71 (EV-A71) and coxsackievirus A16 (CV-A16) are the predominant causes of HFMD epidemics worldwide, EV-A71 has emerged as a major neurovirulent virus responsible for severe neurological complications and fatal outcomes. HFMD is a serious health threat and economic burden across the Asia-Pacific region. Inactivated EV-A71 vaccines have elicited protection against EV-A71 but not against CV-A16 infections in large efficacy trials. The current development of a bivalent inactivated EV-A71/CV-A16 vaccine is the next step toward that of multivalent HFMD vaccines. These vaccines should ultimately include other prevalent pathogenic coxsackieviruses A (CV-A6 and CV-A10), coxsackieviruses B (B3 and B5) and echovirus 30 that often co-circulate during HFMD epidemics and can cause severe HFMD, aseptic meningitis and acute viral myocarditis. The prospect and challenges for the development of such multivalent vaccines are discussed.

show abstract

“…It did not cause any side effects and did not accelerate the development of diabetes in NOD mice, even if the natural CBV1 infection did so. VLP-based CBV3 vaccine induced high neutralizing antibody responses in mice as well [79]. These experimental vaccine studies have demonstrated the feasibility of vaccine production against CBVs: both the traditional inactivated vaccines and VLP-based vaccines are highly immunogenic.…”

Section: Current Prospects In the Vaccine Developmentmentioning

confidence: 95%

Developing a vaccine for Type 1 diabetes through targeting enteroviral infections

Hyöty¹,

Knip²

2014

Expert Review of Vaccines

Self Cite

View full text Add to dashboard Cite

Type 1 diabetes (T1D) is a chronic disease caused by the destruction of insulin producing β-cells in the pancreas. Studies carried out during the past decades have implied that enteroviruses could be an important causative agent. These findings have generated efforts aiming at developing vaccines against these viruses and testing their efficacy against T1D in clinical trials. Extensive work has been carried out to define the serotype of enteroviruses which are linked to T1D and which should be included in the vaccine, and experimental vaccines have been shown to be effective and safe in mouse models. Large-scale studies are currently in progress to increase the confidence in the scientific concept of the enterovirus-diabetes association, paralleling the efforts aimed at starting the clinical development of the vaccine. This review summarizes recent progress in this field and the scenarios regarding this development process.

show abstract

Coxsackievirus B3 VLPs purified by ion exchange chromatography elicit strong immune responses in mice

Cited by 40 publications

References 43 publications

Intricacies of cardiac damage in coxsackievirus B3 infection: Implications for therapy

Intricacies of cardiac damage in coxsackievirus B3 infection: Implications for therapy

Is a multivalent hand, foot, and mouth disease vaccine feasible?

Developing a vaccine for Type 1 diabetes through targeting enteroviral infections

Contact Info

Product

Resources

About